UK markets closed
  • FTSE 100

    6,938.56
    +0.32 (+0.00%)
     
  • FTSE 250

    22,372.26
    +7.39 (+0.03%)
     
  • AIM

    1,265.62
    +1.93 (+0.15%)
     
  • GBP/EUR

    1.1473
    -0.0040 (-0.35%)
     
  • GBP/USD

    1.3874
    +0.0031 (+0.23%)
     
  • BTC-GBP

    36,349.85
    -2,879.09 (-7.34%)
     
  • CMC Crypto 200

    1,158.71
    +34.81 (+3.10%)
     
  • S&P 500

    4,182.25
    +47.27 (+1.14%)
     
  • DOW

    34,048.23
    +232.33 (+0.69%)
     
  • CRUDE OIL

    62.14
    +0.71 (+1.16%)
     
  • GOLD FUTURES

    1,776.10
    -5.90 (-0.33%)
     
  • NIKKEI 225

    29,020.63
    -167.54 (-0.57%)
     
  • HANG SENG

    29,078.75
    +323.41 (+1.12%)
     
  • DAX

    15,279.62
    -40.90 (-0.27%)
     
  • CAC 40

    6,257.94
    -9.34 (-0.15%)
     

Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021

Achilles Therapeutics
·1-min read

Achilles Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2021

London, UK 10 March 2021 – Achilles Therapeutics plc (“Achilles” or the “Company”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that an abstract was selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held in a virtual format from April 10-15, 2021.

Details of the abstract and poster presentation are as follows:

Abstract Title: Characterization of a novel clonal neoantigen reactive T cell (cNeT) product through a comprehensive translational research program
Poster Number:
1508
Poster Session Category / Title:
Immunology / Adoptive Cell Therapy

The abstract and full session details can be found at www.aacr.org. The AACR poster website will be launched on Saturday, April 10, 2021.

About Achilles Therapeutics

Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

Further information:

Lee M. Stern – VP, IR & External Communications
+1 (332) 373-2634
l.stern@achillestx.com

Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
+44 (0) 203 709 5000
achillestx@consilium-comms.com